U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H31FO6
Molecular Weight 422.487
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUDROCORTISONE ACETATE

SMILES

[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

InChIKey=SYWHXTATXSMDSB-GSLJADNHSA-N
InChI=1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H31FO6
Molecular Weight 422.487
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.2ndchance.info/addison's-florinef.pdf

Fludrocortisone acetate (approved as Florinef) is a synthetic adrenocortical steroid possessing very potent mineralcorticoid properties and high glucocorticoid activity. Main indications are Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt losing adrenogenital syndrome.

Originator

Curator's Comment: refernce was retrived from https://www.researchgate.net/publication/284208027_Fludrocortisone_Acetate

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P22199
Gene ID: 25672.0
Gene Symbol: Nr3c2
Target Organism: Rattus norvegicus (Rat)
1.07 nM [Kd]
Target ID: P08235
Gene ID: 4306.0
Gene Symbol: NR3C2
Target Organism: Homo sapiens (Human)
Target ID: P06536
Gene ID: 24413.0
Gene Symbol: Nr3c1
Target Organism: Rattus norvegicus (Rat)
Target ID: P04150
Gene ID: 2908.0
Gene Symbol: NR3C1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FLORINEF

Approved Use

Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.

Launch Date

1955
Primary
FLORINEF

Approved Use

Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.

Launch Date

1955
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1241.1 pg/mL
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.19 μg/L
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3275.8 pg × h/mL
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.25 μg × h/L
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.57 h
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.35 h
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.3 mg 1 times / day multiple, oral
Highest studied dose
Dose: 0.3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: anuric patients with symptomatic hypotension
Population Size: 5
Sources:
Other AEs: Serum potassium decreased, Rise in blood pressure...
Other AEs:
Serum potassium decreased (5 patients)
Rise in blood pressure (5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Rise in blood pressure 5 patients
0.3 mg 1 times / day multiple, oral
Highest studied dose
Dose: 0.3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: anuric patients with symptomatic hypotension
Population Size: 5
Sources:
Serum potassium decreased 5 patients
0.3 mg 1 times / day multiple, oral
Highest studied dose
Dose: 0.3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: anuric patients with symptomatic hypotension
Population Size: 5
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

PubMed

PubMed

TitleDatePubMed
Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis.
2002
[Primary adrenal insufficiency due to autoimmune adrenalitis].
2002 Aug
Outcomes for laparoscopic bilateral adrenalectomy.
2002 Aug
Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
2002 Aug
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
2002 Aug 21
Reducing mortality in sepsis: new directions.
2002 Dec
Chronic unexplained fatigue.
2002 Dec
Treatment of orthostatic hypotension.
2002 Dec
Salt losing nephropathy simulating congenital adrenal hyperplasia in an infant.
2002 Jul
A footnote on the origin of fluorosteroids.
2002 Jul
Screening and diagnosis of primary aldosteronism.
2002 Jul-Aug
Yoghurt biotherapy: contraindicated in immunosuppressed patients?
2002 Jun
Cortisol replacement for severe sepsis and septic shock: what should I do?
2002 Jun
Orthostatic hypotension.
2002 May
[Generic carbamazepine-induced subacute adrenal insufficiency?].
2002 Nov
Dysautonomias: clinical disorders of the autonomic nervous system.
2002 Nov 5
[Diabetic neuropathy--concept, staging, diagnosis, treatment].
2002 Oct
Recently published papers: new evidence for old debates, new drugs and some timely reminders.
2002 Oct
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma.
2002 Oct
Hyperaldosteronism: the internist's hypertensive disease.
2002 Oct
The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development.
2002 Sep
A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke.
2003
Neurocardiogenic syncope in children : current concepts in diagnosis and management.
2003
Sepsis clinical knowledge: a role of steroid treatment.
2003 Apr
Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?
2003 Apr
Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension.
2003 Apr
Monozygotic twins with congenital adrenal hyperplasia: long-term endocrine evaluation and gene analysis.
2003 Apr-May
Association between supine hypertension and orthostatic hypotension in autonomic failure.
2003 Aug
Primary aldosteronism and hypertensive disease.
2003 Aug
Recently published papers: a number of treatment controversies.
2003 Feb
Chronic fatigue syndrome and Addison's disease.
2003 Feb
Successful treatment of severe orthostatic hypotension with erythropoietin.
2003 Jan
[Investigation of hyperaldosteronism in the hypertensive patient. Why? When? How?].
2003 Jan
Drug treatment of orthostatic hypotension and vasovagal syncope.
2003 Jan-Feb
Treating interdialytic hyperkalemia with fludrocortisone.
2003 Jan-Feb
Serum leptin levels in patients with 21-hydroxylase deficiency before and after treatment.
2003 Jan-Mar
Automated coupling of capillary-HPLC to matrix-assisted laser desorption/ionization mass spectrometry for the analysis of small molecules utilizing a reactive matrix.
2003 Jul
Neurologic complications following treatment of canine hypoadrenocorticism.
2003 Jun
Impact of smoking on the response to treatment of thyroid associated ophthalmopathy.
2003 Jun
[A 47-year-old man with "pure autonomic failure" and pernicious anemia].
2003 Jun 13
Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study.
2003 Jun 15
Stability of fludrocortisone acetate solutions prepared from tablets and powder.
2003 Mar
Parkinsonism associated with Addison's disease.
2003 Mar
Granulomatous interstitial nephritis.
2003 Mar
Congenital adrenal hypoplasia presenting as a chronic respiratory condition.
2003 Mar
Simultaneous quantification of budesonide and its two metabolites, 6beta-hydroxybudesonide and 16alpha-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry.
2003 Mar-Apr
Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.
2003 Mar-Apr
Hyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison's disease.
2003 May
Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.
2003 May
Corticosteroid insufficiency in acutely ill patients.
2003 May 22
Patents

Sample Use Guides

0.05mg to 0.3mg FLORINEF (Fludrocortisone acetate) daily (depends on indication)
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:17:57 GMT 2023
Edited
by admin
on Fri Dec 15 15:17:57 GMT 2023
Record UNII
V47IF0PVH4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUDROCORTISONE ACETATE
EP   JAN   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
FLORINEF
Brand Name English
FLUDROCORTISONE ACETATE [JAN]
Common Name English
FLUDROCORTISONI ACETAS [WHO-IP LATIN]
Common Name English
FLUDROCORTISONE ACETATE [USP-RS]
Common Name English
FLUDROCORTISONE 21-ACETATE [MI]
Common Name English
FLUDROCORTISONE ACETATE [EP MONOGRAPH]
Common Name English
SCHEROFLURON
Common Name English
NSC-15186
Code English
FLUDROCORTISONE ACETATE [WHO-IP]
Common Name English
9-Fluoro-11β,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate
Systematic Name English
FLUOROCORTISOL ACETATE
Common Name English
FLUDROCORTISONE ACETATE [USP MONOGRAPH]
Common Name English
Fludrocortisone acetate [WHO-DD]
Common Name English
FLUDROCORTISONE ACETATE [VANDF]
Common Name English
FLUDROCORTISONE ACETATE [ORANGE BOOK]
Common Name English
FLUDROCORTISONE ACETATE [MART.]
Common Name English
PREGN-4-ENE-3,20-DIONE, 21-(ACETYLOXY)-9-FLUORO-11,17-DIHYDROXY-, (11.BETA.)-
Systematic Name English
FLUDROCORTISONE 21-ACETATE
MI  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C1103
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
DAILYMED
V47IF0PVH4
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUDROCORTISONE ACETATE
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Adrenal hormone. Storage: Fludrocortisone acetate should be kept in a well-closed container, protected from light. Additional information: Fludrocortisone acetate is hygroscopic. Definition: Fludrocortisone acetate contains not less than 96.0% and not more than 104.0% of C23H31FO6, calculated with reference to the dried substance.
FDA UNII
V47IF0PVH4
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
NSC
15186
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
DRUG CENTRAL
1191
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID2023062
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-180-4
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
PUBCHEM
225609
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
CAS
514-36-3
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201010
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
CHEBI
5102
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
RS_ITEM_NUM
1273003
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
MERCK INDEX
m5431
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY Merck Index
EVMPD
SUB02209MIG
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
DRUG BANK
DBSALT000659
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
SMS_ID
100000092613
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY
RXCUI
165516
Created by admin on Fri Dec 15 15:17:57 GMT 2023 , Edited by admin on Fri Dec 15 15:17:57 GMT 2023
PRIMARY RxNorm
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY